Systematic review of the pharmacoeconomics of Parkinson disease medications

References

• Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583–1590.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018 Nov;17(11);939–953.
   PubMed Web of Science ®Google Scholar
• GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol. 2017 Nov;16(11):877–897.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184.
   PubMed Web of Science ®Google Scholar
• Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010 Jun;67(6):715–725.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 Mar–Apr;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005 Oct;20(10):1255–1263.
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Westman E, Ballard C, et al. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012 Aug;11(8):697–707.
   PubMed Web of Science ®Google Scholar
• Kadastik-Eerme L, Taba N, Asser T, et al. Factors associated with motor complications in Parkinson’s disease. Brain Behav. 2017 Oct;7(10):e00837.
   PubMed Web of Science ®Google Scholar
• Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006 Dec;63(12):1756–1760. .
   PubMed Web of Science ®Google Scholar
• Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology. 2004 Jan 13;62(1 Suppl 1):S56–S63.
   PubMed Web of Science ®Google Scholar
• Johnson SJ, Diener MD, Kaltenboeck A, et al. An economic model of Parkinson’s disease: implications for slowing progression in the United States. Mov Disord. 2013 Mar;28(3):319–326.
   PubMed Web of Science ®Google Scholar
• Bloem BR, Grimbergen YA, Cramer M, et al. Prospective assessment of falls in Parkinson’s disease. J Neurol. 2001 Nov;248(11):950–958.
   PubMed Web of Science ®Google Scholar
• Arasalingam A, Clarke CE. Reasons for Parkinson’s disease admissions in a large inner city hospital. Parkinsonism Relat Disord. 2014 Feb;20(2):237–238.
   PubMed Web of Science ®Google Scholar
• Hunter PC, Crameri J, Austin S, et al. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):579–583.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384–386. Epub 2006 Nov 2.
   PubMed Web of Science ®Google Scholar
• Pechevis M, Clarke CE, Vieregge P, et al. Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005 Dec;12(12):956–963.
   PubMed Web of Science ®Google Scholar
• Findley LJ. The economic impact of Parkinson’s disease. Parkinsonism Relat Disord. 2007 Sep;13(Suppl):S8–S12.
   PubMed Web of Science ®Google Scholar
• Suh DC, Pahwa R, Mallya U. Treatment patterns and associated costs with Parkinson’s disease levodopa induced dyskinesia. J Neurol Sci. 2012 Aug 15;319(1–2):24–31. Epub 12 Jun 2.
   PubMed Web of Science ®Google Scholar
• Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord. 2013 Mar;28(3):311–318.
   PubMed Web of Science ®Google Scholar
• Noyes K, Liu H, Li Y, et al. Economic burden associated with Parkinson’s disease on elderly medicare beneficiaries. Mov Disord. 2006 Mar;21(3):362–372.
   PubMed Web of Science ®Google Scholar
• Huse DM, Schulman K, Orsini L, et al. Burden of illness in PARKINSON’S disease. Mov Disord. 2005 Nov;20(11):1449–1454.
   PubMed Web of Science ®Google Scholar
• Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474–480.
   PubMed Web of Science ®Google Scholar
• Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson’s disease. Mov Disord. 1998 Mar;13(2):249–254.
   PubMed Web of Science ®Google Scholar
• Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord. 2003 Oct;18(10):1139–1145.
   PubMed Web of Science ®Google Scholar
• Lindgren P. Economic evidence in Parkinson’s disease: a review. Eur J Health Econ. 2004 Oct;5(Suppl 1):S63–S66.
   PubMedGoogle Scholar
• Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
   Google Scholar
• CADTH Common Drug Reviews. pharmacoeconomic review report: apomorphine (Movapo): (Paladin Labs Inc): indication: the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced parkinson’s disease. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright (c) 2018 Canadian Agency for Drugs and Technologies in Health; 2018.
   Google Scholar
• Arnold RJG, Layton A, Rustay NR, et al. Cost-effectiveness of extended-release carbidopa-levodopa for advanced parkinson’s disease. Am J Pharm Benefits. 2017;9(1):23‐29.
   Web of Science ®Google Scholar
• Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson’s disease: a decision-analytic model. Value Health. 2001 Jul–Aug;4(4):308–315.
   PubMedGoogle Scholar
• Findley LJ, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson’s disease patients with wearing-off. Curr Med Res Opin. 2005 Jul;21(7):1005–1014.
   PubMed Web of Science ®Google Scholar
• Francois C, Hauser RA, Aballea S, et al. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data. J Med Econ. 2016;19(5):515–525.
   PubMed Web of Science ®Google Scholar
• Groenendaal H, Tarrants ML, Armand C. Treatment of advanced Parkinson’s disease in the United States A cost-utility model. Clin Drug Investig. 2010;30(11):789–798.
   PubMed Web of Science ®Google Scholar
• Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson’s disease in the UK setting an economic markov model evaluation. Drugs Aging. 2009;26(9):791–801.
   PubMed Web of Science ®Google Scholar
• Kalabina S, Belsey J, Pivonka D, et al. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales. J Med Econ. 2018 Nov;28:1–33.
   Google Scholar
• Kristiansen IS, Bingefors K, Nyholm D, et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden: an exploratory study. Appl Health Econ Health Policy. 2009;7(3):167–180.
   PubMedGoogle Scholar
• Lindgren P, Jonsson B, Duchane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. Eur J Health Econ. 2003;4(1):37–42.
   PubMedGoogle Scholar
• Linna M, Taimela E, Apajasalo M, et al. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease. Expert Rev Pharmacoecon Outcomes Res. 2002 Apr;2(2):91–97.
   PubMedGoogle Scholar
• Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK. J Med Econ. 2011;14(5):584–593.
   PubMedGoogle Scholar
• Lowin J, Sail K, Baj R, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017 Nov;20(11):1207–1215.
   PubMed Web of Science ®Google Scholar
• Lundqvist C, Beiske AG, Reiertsen O, et al. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in parkinson patients. J Neurol. 2014 Dec;261(12):2438–2445.
   PubMed Web of Science ®Google Scholar
• Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson’s disease: a Markov process analysis. Value Health. 2001 Jul–Aug;4(4):316–328.
   PubMedGoogle Scholar
• Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced parkinson’s disease: SCOPE study. J Med Econ. 2013;16(2):191–201.
   PubMedGoogle Scholar
• van Boven JF, Novak A, Driessen MT, et al. Economic evaluation of ropinirole prolonged release for treatment of Parkinson’s disease in the Netherlands. Drugs Aging. 2014 Mar;31(3):193–201.
   PubMed Web of Science ®Google Scholar
• Vossius C, Nilsen OB, Larsen JP. Health state values during the first year of drug treatment in early-stage Parkinson’s disease a prospective, population-based, cohort study. Drugs Aging. 2009;26(11):973–980.
   PubMed Web of Science ®Google Scholar
• Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of parkinson’s disease in the UK and Germany. J Med Econ. 2015 Feb;18(2):155–165.
   PubMed Web of Science ®Google Scholar
• Hudry J, Rinne JO, Keranen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Ann Pharmacother. 2006 Apr;40(4):651–657.
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trial. Med Decis Making. 2004 Sep–Oct;24(5):472–485.
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG, et al. Pramipexole and levodopa in early Parkinson’s Disease - dynamic changes in cost effectiveness. PharmacoEconomics. 2005;23(12):1257–1270.
   PubMed Web of Science ®Google Scholar
• Palhagen SE, Sydow O, Johansson A, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced parkinson’s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17–23.
   PubMed Web of Science ®Google Scholar
• Palmer CS, Nuijten MJ, Schmier JK, et al. Cost effectiveness of treatment of Parkinson’s disease with entacapone in the United States. Pharmacoeconomics. 2002;20(9):617–628.
   PubMed Web of Science ®Google Scholar
• Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson’s disease in Japan. PharmacoEconomics. 2001;19(8):875–886.
   PubMed Web of Science ®Google Scholar
• Willan AR, Goeree R, Pullenayegum EM, et al. Economic evaluation of rivastigmine in patients with Parkinson’s disease dementia. PharmacoEconomics. 2006;24(1):93–106.
   PubMed Web of Science ®Google Scholar
• Munro Neville A, Parsons RW, Askmark H, et al. Treatment of advanced Parkinson’s disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. Parkinsonism Relat Disord. 2012 [Cited 2012 June 01];18(5):686–687.
   PubMed Web of Science ®Google Scholar
• Garcia-Gordillo M, Del Pozo-Cruz B, Adsuar JC, et al. Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson’s disease population sample. Qual Life Res. 2014 May;23(4):1315–1326.
   PubMed Web of Science ®Google Scholar
• Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. Neurology. 2015 Feb 24;84(8):794–802.
   PubMed Web of Science ®Google Scholar
• Dodel R, Jonsson B, Reese JP, et al. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson’s disease. Mov Disord. 2014 Feb;29(2):169–176.
   PubMed Web of Science ®Google Scholar
• Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making. 2007 May–Jun;27(3):327–334.
   PubMed Web of Science ®Google Scholar